文献速递脑血管病

靶向抑制对侧半球mGlu5受体改善卒中后功能恢复

Targeted Inhibition of mGlu5 Receptors in the Contralesional Hemisphere Improves Functional Recovery After Stroke.
PubMed 文献 · Stroke · 2026-02-18

研究利用光药理学在永久性大脑中动脉闭塞小鼠模型中定位mGlu5受体负性变构调节剂(NAM)的促恢复作用位点。全身给药alloswitch-1或光激活JF-NP-26后,在对侧躯体感觉皮层调控药物活性可快速增强或消除功能恢复,而同侧调控无效。结论指出对侧同源躯体感觉皮层是全身mGlu5受体NAM促卒中后恢复的关键作用部位。

要点

  • 全身mGlu5受体NAM的促恢复作用依赖于对侧躯体感觉皮层。
  • 光调控对侧皮层药物活性可在5分钟内改变功能恢复。
  • 同侧皮层调控药物活性不影响恢复,且治疗不改变梗死体积。

核心结论

  • 对侧同源躯体感觉皮层是全身mGlu5受体NAM增强卒中后恢复过程的关键作用部位。
  • 靶向光调控药物可能成为未来增强卒中后功能恢复的治疗策略。

研究设计与样本

  • C57Bl/6小鼠永久性大脑中动脉闭塞卒中模型。
  • 使用光可激活JF-NP-26或光可失活alloswitch-1两种mGlu5受体NAM进行光药理学调控。

主要发现

  • 永久性大脑中动脉闭塞导致2项行为测试可测的感觉运动缺陷。
  • 卒中后30分钟或48小时全身给予alloswitch-1均增强恢复。
  • 对侧躯体感觉皮层给予失活光快速消除促恢复效应,同一区域光再激活后恢复。
  • 同侧组织激活或失活alloswitch-1均未观察到促恢复效应。
  • 对侧同源躯体感觉皮层光激活JF-NP-26在照射后5分钟内增强功能恢复,同侧激活无效。

临床怎么用

  • 提示全身mGlu5受体NAM的促恢复效应可通过靶向对侧躯体感觉皮层实现。
  • 光药理学调控策略可能为未来精准增强卒中后恢复提供方向。

局限性

  • 研究为小鼠模型,结论尚未在人类卒中患者中验证。
  • 光药理学干预需光照射,临床转化存在技术挑战。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Understanding circuit-level changes that either enhance or impair the brain's capacity for recovery will inform the design of more specific, targeted interventions to enhance recovery from stroke. We previously reported that pharmacological blockade of mGlu5 (type-5 metabotropic glutamate) receptors improves recovery of sensorimotor function in rodent models of stroke, concomitant with restoration of functional connectivity in the sensorimotor cortex contralateral to the infarct. Here, we applied photopharmacology and light-activatable/deactivatable mGlu5 receptor negative allosteric modulators (NAMs) to localize when and where in the brain the recovery-enhancing effects occur from systemically administered mGlu5 receptor NAMs. METHODS: Stroke was induced in C57Bl/6 mice by permanent middle cerebral artery occlusion. Mice were treated with either JF-NP-26 (7-(Diethylamino)-2-oxo-2H‑chromen‑4‑yl)methyl (2‑((3‑fluorophenyl)ethynyl)‑4,6‑dimethylpyridin‑3‑yl)carbamate) or alloswitch-1. JF-NP-26 is a caged derivative of the mGlu5 receptor NAM, raseglurant, inactive on its own, and can be activated by visible light of 405 nm. Alloswitch-1 is an active mGlu5 receptor NAM that can be inactivated by light of 405 nm and subsequently reactivated by light of 520 nm. RESULTS: Permanent middle cerebral artery occlusion caused a sensorimotor deficit measured by 2 behavioral tests. Systemic administration of alloswitch-1 either 30 minutes or 48 hours after stroke enhanced recovery. This effect was rapidly abrogated when deactivating light was delivered to the contralateral somatosensory cortex and was subsequently restored by light-induced reactivation in the same region. No recovery-enhancing effects were observed when alloswitch-1 was activated or deactivated in the ipsilateral tissue. Specific light-induced activation of JF-NP-26 in the homotopic contralateral but not the ipsilateral somatosensory cortex enhanced functional recovery within 5 minutes after irradiation. None of the treatments changed infarct sizes. CONCLUSIONS: These findings demonstrate that the homotopic contralateral somatosensory cortex is a key site of action of systemic mGlu5 receptor NAMs in enhancing restorative processes important for recovery after stroke. Targeted, light-modulated drugs represent a potential future therapeutic strategy to enhance recovery of function after stroke.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Mastroiacovo F, Notartomaso S, Moyanova SG, et al. Targeted Inhibition of mGlu5 Receptors in the Contralesional Hemisphere Improves Functional Recovery After Stroke. Stroke. 2026. PMID: 41705338. doi:10.1161/STROKEAHA.125.054261

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。